Zobrazeno 1 - 10
of 226
pro vyhledávání: '"Shigeki, Ohtake"'
Autor:
Satoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Yoshiko Atsuta, Noriko Doki, Shingo Kurahashi, Yasunori Ueda, Nobuaki Dobashi, Tomoya Maeda, Yasuhiro Taniguchi, Masatsugu Tanaka, Shinichi Kako, Tatsuo Ichinohe, Takahiro Fukuda, Shigeki Ohtake, Yuichi Ishikawa, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki, on behalf of Japan Adult Leukemia Study Group
Publikováno v:
HemaSphere, Vol 7, Iss 6, p e899 (2023)
Externí odkaz:
https://doaj.org/article/d7e5a0987ca542338d175708144ea6e9
Autor:
Yuichi Ishikawa, Naomi Kawashima, Yoshiko Atsuta, Isamu Sugiura, Masashi Sawa, Nobuaki Dobashi, Hisayuki Yokoyama, Noriko Doki, Akihiro Tomita, Toru Kiguchi, Shiro Koh, Heiwa Kanamori, Noriyoshi Iriyama, Akio Kohno, Yukiyoshi Moriuchi, Noboru Asada, Daiki Hirano, Kazuto Togitani, Toru Sakura, Maki Hagihara, Tatsuki Tomikawa, Yasuhisa Yokoyama, Norio Asou, Shigeki Ohtake, Itaru Matsumura, Yasushi Miyazaki, Tomoki Naoe, Hitoshi Kiyoi
Publikováno v:
Blood Advances, Vol 4, Iss 1, Pp 66-75 (2020)
Abstract: The prognostic impact of KIT mutation on core-binding factor acute myeloid leukemia (CBF-AML) remains controversial. We registered 199 newly diagnosed de novo CBF-AML patients, aged 16 to 64 years, who achieved complete remission. They rece
Externí odkaz:
https://doaj.org/article/d8f98219f90f425d95e4fd4f64876f2b
Autor:
Satoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Noriko Doki, Shingo Kurahashi, Yasunori Ueda, Nobuaki Dobashi, Tomoya Maeda, Yasuhiro Taniguchi, Masatsugu Tanaka, Shinichi Kako, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Atsuta, Shigeki Ohtake, Yuichi Ishikawa, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki
Publikováno v:
Blood. 140:6030-6032
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c166898cb242f83cdf053408208d9ac
https://doi.org/10.1182/blood-2022-165864
https://doi.org/10.1182/blood-2022-165864
Autor:
Fumihiko Hayakawa, Tomoko Hata, Yasushi Miyazaki, Shigeki Ohtake, Mitsuhiro Matsuda, Masahiro Onoda, Isamu Sugiura, Yukiyasu Ozawa, Maki Hagihara, Yukio Kobayashi, Tomoki Naoe, Toru Sakura, Noriko Doki, Hiroyuki Fujita, Hisayuki Yokoyama, Yoshihiro Hatta, Ryuko Cho, Yuichi Ishikawa, Nobuhiro Hiramoto, Masatsugu Tanaka, Toshiro Ito, Nobuaki Dobashi, Shinichi Kako, Tsuyoshi Kamae, Yasuhiro Taniguchi, Masaaki Tsuji, Shin Fujisawa, Yasunori Ueda, Yoshiko Atsuta, Satoshi Nishiwaki, Daiki Hirano, Youko Suehiro
Publikováno v:
Blood Advances
Key Points Dasatinib-based 2-step induction resulted in a 100% CR rate with minimal toxicities and 53% MRD negativity.This protocol treatment increased the number of HSCTs in CR1, thereby improving 3-year EFS.
Visual Abstract
The standard t
Visual Abstract
The standard t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f41ec0fbea24cb5e015b04c7a36f7d7b
https://doi.org/10.1182/bloodadvances.2021004607
https://doi.org/10.1182/bloodadvances.2021004607
Autor:
Yasuhito Nannya, Magnus Tobiasson, Shinya Sato, Elsa Bernard, Shigeki Ohtake, June Takeda, Maria Creignou, Lanying Zhao, Manabu Kusakabe, Yuhei Shibata, Nobuhiko Nakamura, Mizuki Watanabe, Nobuhiro Hiramoto, Yusuke Shiozawa, Yuichi Shiraishi, Hiroko Tanaka, Kenichi Yoshida, Nobuyuki Kakiuchi, Hideki Makishima, Masahiro Marshall Nakagawa, Kensuke Usuki, Mitsumasa Watanabe, Kazunori Imada, Hiroshi Handa, Masataka Taguchi, Toru Kiguchi, Kazuma Ohyashiki, Takayuki Ishikawa, Akifumi Takaori-Kondo, Hisashi Tsurumi, Senji Kasahara, Shigeru Chiba, Tomoki Naoe, Satoru Miyano, Elli Papaemmanuil, Yasushi Miyazaki, Eva Hellström Lindberg, Seishi Ogawa
Publikováno v:
Blood Advances.
Azacitidine is a mainstay of therapy for MDS-related diseases. The purpose of our study is to elucidate the effect of gene mutations on hematological response and overall survival (OS), particularly focusing on their post-treatment clone size. We enr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f90bbc4fc5144aac390a67a2b01bd9c1
https://doi.org/10.1182/bloodadvances.2022009564
https://doi.org/10.1182/bloodadvances.2022009564
Autor:
Ken Ishiyama, Noriharu Nakagawa, Kensuke Usuki, Satoru Takada, Tatsuki Tomikawa, Hiroshi Handa, Yuna Katsuoka, Daiki Hirano, Nobuo Sezaki, Masahiko Sumi, Shin Fujisawa, Yasuhiro Taniguchi, Atsuko Mugitani, Takuro Yoshimura, Eiichi Ohtsuka, Ken Takase, Youko Suehiro, Shuichi Ota, Tomohiro Kajiguchi, Tomoya Maeda, Masahide Yamamoto, Shigeki Ohtake, Akira Katsumi, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is the sole curative therapy for myelodysplastic syndromes (MDS). However, whether bridging therapy (BRT) including azacitidine (AZA) and combination chemotherapy (CCT) prior to allo-SCT s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b739a6d580d7bb7f9e5237a9f936326c
https://doi.org/10.21203/rs.3.rs-2271688/v1
https://doi.org/10.21203/rs.3.rs-2271688/v1
Autor:
Yasushi Miyazaki, Naomi Kawashima, Heiwa Kanamori, Maki Hagihara, Norio Asou, Kensuke Usuki, Hitoshi Kiyoi, Tomoki Naoe, Miki Kobayashi, Shigeki Ohtake, Yoshiko Atsuta, Masashi Sawa, Akio Kohno, Yuichi Ishikawa, Tomoya Maeda, Masaki Hayashi, Itaru Matsumura, Hiroshi Matsuoka, Akihiro Tomita, Emiko Sakaida, Yukiyasu Ozawa
Publikováno v:
Cancer Science
In this phase II multicenter study (JALSG AML209‐FLT3‐SCT), we aimed to prospectively elucidate the role of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) at first complete remission (CR1) for FLT3‐internal tandem duplication
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80abc550b7b736b3dc459311d2db0288
https://doi.org/10.1111/cas.14448
https://doi.org/10.1111/cas.14448
Autor:
Yasushi, Miyazaki, Toru, Kiguchi, Shinya, Sato, Kensuke, Usuki, Ken, Ishiyama, Yoshikazu, Ito, Takahiro, Suzuki, Jun, Taguchi, Shigeru, Chiba, Nobuaki, Dobashi, Akihiro, Tomita, Hironori, Harada, Hiroshi, Handa, Shigeo, Horiike, Tomoya, Maeda, Mitsuhiro, Matsuda, Motoshi, Ichikawa, Tomoko, Hata, Sumihisa, Honda, Satoshi, Iyama, Hitoshi, Suzushima, Yukiyoshi, Moriuchi, Toshiro, Kurokawa, Kenichi, Yokota, Shigeki, Ohtake, Takahiro, Yamauchi, Itaru, Matsumura, Hitoshi, Kiyoi, Tomoki, Naoe
Publikováno v:
International journal of hematology. 116(2)
The hypomethylating agent azacitidine (AZA) significantly extends overall survival (OS) in patients with higher risk myelodysplastic syndromes (MDS), when compared with other conventional care regimens, including supportive care and low-dose and inte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::75de38da0228ded09ffe8328bafc298b
https://pubmed.ncbi.nlm.nih.gov/35508695
https://pubmed.ncbi.nlm.nih.gov/35508695
Autor:
Naoto Takahashi, Yuki Fujioka, Yoshiko Atsuta, Hiroyoshi Nishikawa, Yosuke Minami, Itaru Matsumura, Yasushi Miyazaki, Shigeki Ohtake, Hitoshi Kiyoi, Daisuke Sugiyama, Masatomo Miura
Publikováno v:
Cancers
Cancers, Vol 13, Iss 5904, p 5904 (2021)
Cancers; Volume 13; Issue 23; Pages: 5904
Cancers, Vol 13, Iss 5904, p 5904 (2021)
Cancers; Volume 13; Issue 23; Pages: 5904
Simple Summary Tyrosine kinase inhibitors (TKIs) have dramatically improved the treatment of chronic myeloid leukemia (CML). Recently, TKIs were discontinued in patients with CML with deep molecular remission, and some patients have been reported to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7ab599e87b1f1ddbd32363836216d14
http://europepmc.org/articles/PMC8657169
http://europepmc.org/articles/PMC8657169
Autor:
Shinichi Kako, Fumihiko Hayakawa, Koichi Miyamura, Junji Tanaka, Kiyotoshi Imai, Junya Kanda, Satoko Morishima, Naoyuki Uchida, Noriko Doki, Kazuhiro Ikegame, Yukiyasu Ozawa, Satoru Takada, Noriko Usui, Shigeki Ohtake, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Atsuta, Yoshinobu Kanda
Publikováno v:
Transplantation and cellular therapy. 28(3)
An HLA-matched relative is the first-choice donor for patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1). The most promising alternative donor is thought to be an HLA-matched unrel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f4117240327b954856da0f651e1d5b1
https://pubmed.ncbi.nlm.nih.gov/34875401
https://pubmed.ncbi.nlm.nih.gov/34875401